Contrast developer Bracco Diagnostics and group purchasing organization Amerinet have added the vendor's Lumason echocardiography contrast agent to their existing contract.
Under the terms of the new deal, Amerinet members will have access to Lumason (formerly known in the U.S. as SonoVue) for contrast echocardiography studies, according to Bracco. Lumason is currently cleared by the U.S. Food and Drug Administration (FDA) for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
